news
New Phase III data for hidradenitis suppurativa biologic released
The IL-17A and IL–17F inhibitor demonstrated positive efficacy and safety in adults with moderate-to-severe hidradenitis suppurativa, new data shows.
List view / Grid view
Hidradenitis suppurativa (HS)
article
Year in review: EPR’s top stories of 2023
EPR wraps up the year with a selection of top stories from 2023, highlighting key trends and topics such as environmental monitoring (EM), quality (QA/QC), manufacturing, regulation and clinical development.
news
Biologic could be first new hidradenitis suppurativa treatment in a decade
The first and only fully human biologic that directly inhibits interleukin-17A has been granted a positive opinion by the Committee for Medicinal Products for Human Use (CHMP).
news
EC approves first high concentration, low-volume adalimumab biosimilar
YuflymaTM (CT-P17) has been approved for the treatment of thirteen chronic inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and psoriatic arthritis, in Europe.
news
NICE recommends five drugs to treat four different conditions
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS.
news
SMC says ‘no’ to Kalydeco and Orkambi in cystic fibrosis
The Scottish Medicines Consortium (SMC) has rejected Kalydeco (ivacaftor) and Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis.
news
NICE recommends adalimumab for hidradenitis suppurativa
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Humira (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy.
news
FDA approves Humira for hidradenitis suppurativa
The US Food and Drug Administration (FDA) has approved AbbVie’s Humira (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa.
news
Abbvie receives Orphan Drug Designation for Humira for the investigational treatment of hidradenitis suppurativa
The US Food and Drug Administration (FDA) has granted Abbvie’s Humira® (adalimumab) Orphan Drug Designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease.
news
AbbVie presents phase II data evaluating the efficacy of Humira® in patients with Hidradenitis Suppurativa (HS), a chronic inflammatory skin disease
AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.1
news
Abbott announces patient enrollment in two phase 3 studies of HUMIRA® (adalimumab)
Abbott today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA® (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa (HS).
